A 90-day oral (dietary) toxicity and mass balance study of corn starch fiber in Sprague Dawley rats

2016 ◽  
Vol 97 ◽  
pp. 57-69 ◽  
Author(s):  
Christine M. Crincoli ◽  
Andrey I. Nikiforov ◽  
Marisa O. Rihner ◽  
Elizabeth A. Lambert ◽  
Melanie A. Greeley ◽  
...  
Keyword(s):  
Mass Balance ◽  
Corn Starch ◽  
Sprague Dawley ◽  
Balance Study ◽  
Sprague Dawley Rats ◽  
Dietary Toxicity ◽  
Mass Balance Study

scholarly journals Antiobesity Activity of Elateriospermum tapos Shell Extract in Obesity-Induced Sprague Dawley Rats

Molecules ◽  
2021 ◽  
Vol 26 (2) ◽  
pp. 321
Author(s):  
Kokila Vani Perumal ◽  
Nor Liyana Ja’afar ◽  
Che Norma Mat Taib ◽  
Nurul Husna Shafie ◽  
Hasnah Bahari
Keyword(s):  
Body Weight ◽  
Corn Starch ◽  
Milk Powder ◽  
Caloric Intake ◽  
Lipid Lowering ◽  
Sprague Dawley ◽  
Triglyceride Accumulation ◽  
Sprague Dawley Rats ◽  
Effective Result ◽  
Lipid Lowering Effect

Obesity is one of the risk factors associated with cardiovascular diseases, hypertension, abnormal liver function, diabetes, and cancers. Orlistat is currently available to treat obesity, but it is associated with adverse side effects. Natural resources are widely used for obesity treatment. Hence, this study aimed to investigate the anti-obesity activity of Elateriospermum tapos (E. tapos) shell extract in obesity induced Sprague Dawley rats. The rats’ obesity was induced by a high-fat (HF) diet made up of 50% standard rat pellet, 20% milk powder, 6% corn starch, and 24% ghee and a cafeteria (CAF) diet such as chicken rolls, salty biscuits, cakes, and cheese snacks. A hot aqueous method for the extraction of E. tapos shells was applied by using 500 mL of distilled water for about 24 h. Various dosages of E. tapos shell extract (10 mg/kg, 100 mg/kg, and 200 mg/kg) were used. At the end of the study, body weight, caloric intake, organ weight, lipid profile, lipoprotein lipase (LPL) activity, and histopathology analysis were carried out. E. tapos shell extract treated groups showed a reduction in body weight, positive lipid-lowering effect, decrements in triglyceride accumulation and LPL activity, and positive improvement in histopathology analysis. A dose of 200 mg/kg showed the most effective result compared to 10 mg/kg and 100 mg/kg doses.

Unequal Absorption of Radiolabeled and Nonradiolabeled Drug from the Oral Dose Leads to Incorrect Estimates of Drug Absorption and Circulating Metabolites in a Mass Balance Study

2019 ◽  
Vol 13 (1) ◽  
pp. 37-44
Author(s):  
Ryan H. Takahashi ◽  
Jae H. Chang ◽  
Jodie Pang ◽  
Xiaorong Liang ◽  
Shuguang Ma
Keyword(s):  
Oral Dose ◽  
Mass Balance ◽  
Specific Activity ◽  
The Body ◽  
Total Drug ◽  
Beagle Dogs ◽  
Balance Study ◽  
Drug Concentrations ◽  
Specific Activities ◽  
Mass Balance Study

Background: Mass balance studies conducted using radiolabeled material (14C or 3H) definitively characterize the Absorption, Metabolism, and Excretion (AME) of a drug. A critical aspect of these studies is that the radiotracer maintains its proportion to total drug from its administration to its complete elimination from the body. In the study of GDC-0276 in beagle dogs, we observed that the 14C radiotracer proportion (specific activity) varied through the study. Method: High resolution-accurate mass spectrometric measurements of 12C and 14C isotopes of GDC- 0276 and its metabolites in plasma and excreta samples were used to determine the apparent specific activities, which were higher than the specific activity of the dosing formulation. Drug concentrations were adjusted to the observed specific activities to correct the readouts for GDC-0276 AME and PK. Results: The enrichment of 14C, which resulted in higher specific activities, was consistent with faster and more extensive absorption of the radiotracer from the dosing formulation. This resulted in overestimating the dose absorbed, the extent of elimination in urine and bile, and the exposures to circulating metabolites. These biases were corrected by the specific activities determined for study samples by mass spectrometry. Conclusion: Assuming that the radiotracer was proportional to total drug throughout a radiolabeled study was not valid in a 14C study in beagle dogs. This presumably resulted from unequal absorption of the radiotracer and nonradiolabeled test articles from the oral dose due to inequivalent solid forms. We were able to provide a more accurate description of the AME of GDC-0276 in dogs by characterizing the differential absorption of the radiotracer.

A Phase 1 Mass Balance Study of 14 C‐Labeled Talazoparib in Patients With Advanced Solid Tumors

2019 ◽  
Author(s):  
Yanke Yu ◽  
Chin‐Hee Chung ◽  
Anna Plotka ◽  
Kevin Quinn ◽  
Haihong Shi ◽  
...  
Keyword(s):  
Mass Balance ◽  
Solid Tumors ◽  
Phase 1 ◽  
Advanced Solid Tumors ◽  
Balance Study ◽  
Mass Balance Study
Sign in / Sign up

Export Citation Format

Share Document